Medical Patent News

RSS

Abviva receives Japanese patent for Mammastatin Serum Assay

Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA).

18 May 2010

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

Teva agrees to settle patent litigation regarding generic version of AstraZeneca's Entocort EC capsules

Teva Pharmaceutical Industries Ltd. announced today that it has entered into an agreement with AstraZeneca to settle patent litigation regarding Teva's U.S. generic version of AstraZeneca's Entocort EC (budesonide) capsules.

18 May 2010

Power3 Medical Products files provisional patent applications with USPTO

Power3 Medical Products, Inc. announced today that it has filed two provisional patent applications with the United States Patent and Trademark Office (USPTO) - one on Alzheimer's disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer's disease patients.

15 May 2010

U.S. Patent and Trademark Office grants patent to Historx's AQUA technology

HistoRx , Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers.

15 May 2010

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.

15 May 2010

IpAuctions schedules sale of Zassi's pouchless ostomy management technology IP portfolio

IpAuctions™ has scheduled a live international corporate sale of the extensive IP portfolio of pouchless ostomy management technologies owned by Zassi Holdings, Inc. Zassi, the Florida-based firm, fosters breakthrough medical devices that are materially evolving the life sciences industry.

15 May 2010

Celsis IVT settles LiverPool patent infringement suit, XenoTech to stop sale of CryoXTreme products

Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.

14 May 2010

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

A newly awarded U.S. Patent will protect TechniScan, Inc's., novel way to image, biopsy and treat breast cancer.

13 May 2010

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced that it has received the Provectus Award presented by MDB Capital Group at the first annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property (IP).

13 May 2010

PositiveID files provisional patent covering glucose level RF sensing technology

PositiveID Corporation announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office covering the interface between a radio frequency ("RF") powered resonant electromechanical drive and the fluids in the interstitial space of a patient for continuous detection of glucose levels in a patient. The interface employs a resonant electromechanical drive for mass sensing and RF communication of glucose levels.

13 May 2010

Solta Medical, Alma Lasers resolve Thermage patent lawsuits

Solta Medical, Inc., Alma Lasers Ltd. and Alma Lasers, Inc. today announced that they have reached an agreement resolving lawsuits involving certain Thermage® patents held by Solta Medical.

12 May 2010

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. patent application 11/418,870, including claims related to Sanger hsa-miR-451. miR-451 is used in the Company's miRview™ mets test, which accurately identifies the primary tumor site in patients with metastatic cancer and Cancer of Unknown Primary (CUP).

11 May 2010

Merck, Glenmark settle ZETIA patent litigation

Merck & Co., Inc. and Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals, Ltd. have reached an agreement to settle their patent litigation involving Glenmark's challenge to Merck's patent covering ZETIA ® (ezetimibe). Specifically, Glenmark challenged Merck's basic compound patent, RE 37,721 (the "721 patent") on numerous grounds.

11 May 2010

Iris Biotechnologies receives two new Canadian patents

Iris BioTechnologies Inc., a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, and recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics, today announced two new Canadian patents.

11 May 2010

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.

10 May 2010

Watson Pharmaceuticals reaches patent litigation settlement with Teva Women's Health

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

10 May 2010

USPTO grants patent for Quick-Med's proprietary NIMBUS polymeric antimicrobial technology

Quick-Med Technologies, Inc., a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, today announced that it has been granted U.S. Patent No. 7,709,694 from the United States Patent and Trademark Office. The patent for company's proprietary NIMBUS polymeric antimicrobial technology is applicable to a variety of base materials including woven and nonwoven fabrics.

7 May 2010

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

MMI-USA expands worldwide patent, trademark programs

MMI-USA, a subsidiary of Memometal Technologies S.A., France, a global leader in the manufacture and development of extremity orthopedics, announced today the expansion of its U.S. and worldwide patent and trademark programs. Memometal recognizes the value of its intellectual property and is committed to protecting its products through aggressive procurement and enforcement of patent and trademark rights.

7 May 2010

Medical Patent News

Abviva receives Japanese patent for Mammastatin Serum Assay

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Teva agrees to settle patent litigation regarding generic version of AstraZeneca's Entocort EC capsules

Power3 Medical Products files provisional patent applications with USPTO

U.S. Patent and Trademark Office grants patent to Historx's AQUA technology

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

IpAuctions schedules sale of Zassi's pouchless ostomy management technology IP portfolio

Celsis IVT settles LiverPool patent infringement suit, XenoTech to stop sale of CryoXTreme products

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

PositiveID files provisional patent covering glucose level RF sensing technology

Solta Medical, Alma Lasers resolve Thermage patent lawsuits

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Merck, Glenmark settle ZETIA patent litigation

Iris Biotechnologies receives two new Canadian patents

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Watson Pharmaceuticals reaches patent litigation settlement with Teva Women's Health

USPTO grants patent for Quick-Med's proprietary NIMBUS polymeric antimicrobial technology

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

MMI-USA expands worldwide patent, trademark programs

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News